First in Ohio to Offer FDA-Approved Inspire™

UH Case Medical Center is the first in Ohio and among the first in the United States to begin offering a new FDA-approved treatment for obstructive sleep apnea (OSA).

The first-of-its-kind, implantable electronic stimulation device, called Inspire™ Upper Airway Stimulation (UAS) therapy, is designed to deliver mild stimulation to the main nerve of the tongue (hypoglossal nerve) on each breathing cycle during sleep. The stimulation is intended to restore tone to key airway muscles and prevent airway collapse.

UH Case Medical Center was one of the clinical sites for the Stimulation Therapy for Apnea Reduction (the STAR trial) study and the findings were published in the New England Journal of Medicine (Jan. 9, 2014). Kingman Strohl, MD, pulmonologist, UH Case Medical Center; Professor of Medicine, Physiology & Biophysics, and General Medical Sciences at Case Western Reserve University School of Medicine; and Director of the Sleep Disorders Program at the Louis Stokes Cleveland VA Medical Center, and Jonathan Baskin, MD, Chief, Otolaryngology – Head & Neck Surgery, Facial Plastic and Reconstructive Surgery, Louis Stokes Cleveland VA Medical Center and an attending physician at UH Case Medical Center were the site principal investigators for the study and co-authors of the NEJM article. The STAR trial results showed that Inspire therapy reduced apnea events by 68 percent and significantly improved key quality of life measures. Inspire therapy is offered in collaboration with specially trained surgeon, Mark Weidenbecher, MD, of UH Ear, Nose & Throat Institute; and Assistant Professor of Otolaryngology, Case Western Reserve University School of Medicine.